drugset / Trial / NCT06635057

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

NCT06635057

Phase 4 Completed 166 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.

Timeline

Start
2024-10-11
Primary completion
2026-04-15
Completion
2026-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirzepatide Peptide Subcutaneous